What's Happening?
Moderna and Merck have announced promising long-term results from their mRNA neoantigen therapy, intismeran autogene, in combination with Merck's Keytruda. The therapy has shown a significant reduction in the risk of recurrence or death in patients with advanced melanoma. The data, derived from the Phase IIb KEYNOTE-942/mRNA-4157-P201 study, indicates a 49% reduction in risk at the five-year mark compared to Keytruda alone. This builds on previous analyses at two and three years, where similar reductions were observed. The study involved patients with high-risk stage three or four melanoma who had undergone complete resection before receiving the treatment. The companies are also conducting a Phase III trial for this combination as an adjuvant
treatment in melanoma, with additional trials underway for lung cancer and renal cell carcinoma.
Why It's Important?
The results from Moderna and Merck's collaboration highlight a significant advancement in the treatment of melanoma, a type of skin cancer known for its high recurrence rate even after surgical removal. By reducing the risk of recurrence or death by nearly half, this combination therapy offers a potential long-term solution for patients with advanced melanoma. This development is crucial as it could lead to improved survival rates and quality of life for patients. Furthermore, the success of this therapy could pave the way for similar approaches in treating other types of cancer, potentially transforming the landscape of cancer treatment and offering hope to many patients and their families.
What's Next?
Moderna and Merck are continuing their efforts to expand the application of their mRNA-Keytruda combination therapy. They are currently enrolling patients for a Phase III trial in lung cancer and a Phase II trial in renal cell carcinoma. These trials aim to explore the efficacy of the therapy in other cancer types, potentially broadening its impact. The ongoing research and development efforts underscore the companies' commitment to advancing cancer treatment and could lead to new therapeutic options for patients with various forms of cancer.
